Literature DB >> 22534318

IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses.

Luca Fania1, Giacomo Caldarola, Ralf Müller, Oliver Brandt, Riccardo Pellicano, Claudio Feliciani, Michael Hertl.   

Abstract

Bullous pemphigoid (BP) is the most common autoimmune bullous disease of the elderly and is associated with IgG and IgE autoantibodies against the hemidesmosomal proteins, BP180 and BP230. The purpose of this study was to characterize the epitope specificity of IgE against defined regions of BP180 and BP230 in 32 BP patients and 21 elderly patients with pruritic disorders who did not yet fulfill all the criteria of BP by immunoblot (IB), ELISA and indirect immunofluorescence microscopy. Our findings show that IgE from BP sera preferentially targets the COOH-terminus of BP230 (IB: 16/32, ELISA: 12/32) and, to a lesser extent, the BP180-NC16A domain (IB: 11/32, ELISA: 9/32). Noteworthy, a subgroup of elderly patients with pruritic dermatoses also showed IgE recognition of BP180-NC16A (IB: 1/21, ELISA: 4/21) and less frequently of BP230 (IB: 2/21, ELISA: 2/21). Thus, IgE recognition of the BP autoantigens is presumably an early pathogenetic event in BP.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22534318     DOI: 10.1016/j.clim.2012.02.003

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  16 in total

Review 1.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 2.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

3.  [Chronic pruritus in autoimmune dermatoses : results of a comparative survey].

Authors:  L Schröder; M Hertl; E Chatzigeorgakidis; N Q Phan; S Ständer
Journal:  Hautarzt       Date:  2012-07       Impact factor: 0.751

Review 4.  [Bullous pemphigoid: diagnosis and therapy].

Authors:  Andrea Kneisel; Michael Hertl
Journal:  Wien Med Wochenschr       Date:  2014-07-31

5.  Deletion of the major bullous pemphigoid epitope region of collagen XVII induces blistering, autoimmunization, and itching in mice.

Authors:  Tiina Hurskainen; Nina Kokkonen; Raija Sormunen; Joanna Jackow; Stefanie Löffek; Raija Soininen; Claus-Werner Franzke; Leena Bruckner-Tuderman; Kaisa Tasanen
Journal:  J Invest Dermatol       Date:  2014-10-13       Impact factor: 8.551

6.  T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid.

Authors:  W J Pickford; V Gudi; A M Haggart; B J Lewis; R Herriot; R N Barker; A D Ormerod
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

Review 7.  Bullous pemphigoid: An immune disorder related to aging (Review).

Authors:  Maria Ludovica Deotto; Alice Spiller; Alvise Sernicola; Mauro Alaibac
Journal:  Exp Ther Med       Date:  2021-11-15       Impact factor: 2.447

Review 8.  Bullous pemphigoid in a 3-month-old infant: case report and literature review of this dermatosis in childhood.

Authors:  Eugenio Galdino de Mendonça Reis-Filho; Tainah de Almeida Silva; Luiza Helena de Lima Aguirre; Carmelia Matos Santiago Reis
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

Review 9.  Immunoglobulin E-Mediated Autoimmunity.

Authors:  Marcus Maurer; Sabine Altrichter; Oliver Schmetzer; Jörg Scheffel; Martin K Church; Martin Metz
Journal:  Front Immunol       Date:  2018-04-09       Impact factor: 7.561

10.  IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants.

Authors:  P C Freire; C H Muñoz; G Stingl
Journal:  Br J Dermatol       Date:  2017-11-28       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.